Browsing by Author "Kinahan, Paul"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    ItemOpen Access
    Proceedings Virtual Imaging Trials in Medicine 2024.
    (ArXiv, 2024-05-08) Abadi, Ehsan; Badano, Aldo; Bakic, Predrag; Bliznakova, Kristina; Bosmans, Hilde; Carton, Ann-Katherine; Frangi, Alejandro; Glick, Stephen; Kinahan, Paul; Lo, Joseph; Maidment, Andrew; Ria, Francesco; Samei, Ehsan; Sechopoulos, Ioannis; Segars, Paul; Tanaka, Rie; Vancoillie, Liesbeth
    This submission comprises the proceedings of the 1st Virtual Imaging Trials in Medicine conference, organized by Duke University on April 22-24, 2024. The listed authors serve as the program directors for this conference. The VITM conference is a pioneering summit uniting experts from academia, industry and government in the fields of medical imaging and therapy to explore the transformative potential of in silico virtual trials and digital twins in revolutionizing healthcare. The proceedings are categorized by the respective days of the conference: Monday presentations, Tuesday presentations, Wednesday presentations, followed by the abstracts for the posters presented on Monday and Tuesday.
  • Thumbnail Image
    ItemOpen Access
    Statistical Issues in Testing Conformance with the Quantitative Imaging Biomarker Alliance (QIBA) Profile Claims.
    (Academic radiology, 2016-04) Obuchowski, Nancy A; Buckler, Andrew; Kinahan, Paul; Chen-Mayer, Heather; Petrick, Nicholas; Barboriak, Daniel P; Bullen, Jennifer; Barnhart, Huiman; Sullivan, Daniel C
    A major initiative of the Quantitative Imaging Biomarker Alliance is to develop standards-based documents called "Profiles," which describe one or more technical performance claims for a given imaging modality. The term "actor" denotes any entity (device, software, or person) whose performance must meet certain specifications for the claim to be met. The objective of this paper is to present the statistical issues in testing actors' conformance with the specifications. In particular, we present the general rationale and interpretation of the claims, the minimum requirements for testing whether an actor achieves the performance requirements, the study designs used for testing conformity, and the statistical analysis plan. We use three examples to illustrate the process: apparent diffusion coefficient in solid tumors measured by MRI, change in Perc 15 as a biomarker for the progression of emphysema, and percent change in solid tumor volume by computed tomography as a biomarker for lung cancer progression.
  • Thumbnail Image
    ItemOpen Access
    Task Group 174 Report: Utilization of [18 F]Fluorodeoxyglucose Positron Emission Tomography ([18 F]FDG-PET) in Radiation Therapy.
    (Medical physics, 2019-10) Das, Shiva K; McGurk, Ross; Miften, Moyed; Mutic, Sasa; Bowsher, James; Bayouth, John; Erdi, Yusuf; Mawlawi, Osama; Boellaard, Ronald; Bowen, Stephen R; Xing, Lei; Bradley, Jeffrey; Schoder, Heiko; Yin, Fang-Fang; Sullivan, Daniel C; Kinahan, Paul
    The use of positron emission tomography (PET) in radiation therapy (RT) is rapidly increasing in the areas of staging, segmentation, treatment planning, and response assessment. The most common radiotracer is 18 F-fluorodeoxyglucose ([18 F]FDG), a glucose analog with demonstrated efficacy in cancer diagnosis and staging. However, diagnosis and RT planning are different endeavors with unique requirements, and very little literature is available for guiding physicists and clinicians in the utilization of [18 F]FDG-PET in RT. The two goals of this report are to educate and provide recommendations. The report provides background and education on current PET imaging systems, PET tracers, intensity quantification, and current utilization in RT (staging, segmentation, image registration, treatment planning, and therapy response assessment). Recommendations are provided on acceptance testing, annual and monthly quality assurance, scanning protocols to ensure consistency between interpatient scans and intrapatient longitudinal scans, reporting of patient and scan parameters in literature, requirements for incorporation of [18 F]FDG-PET in treatment planning systems, and image registration. The recommendations provided here are minimum requirements and are not meant to cover all aspects of the use of [18 F]FDG-PET for RT.
  • Thumbnail Image
    ItemOpen Access
    Virtual imaging trials in medicine: A brief takeaway of the lessons from the first international summit.
    (Medical physics, 2024-12) Samei, Ehsan; Abadi, Ehsan; Bakic, Predrag; Bliznakova, Kristina; Bosmans, Hilde; Carton, Ann-Katherine; Frangi, Alejandro F; Glick, Stephen; Lo, Joseph Y; Kinahan, Paul; Maidment, Andrew; Ria, Francesco; Sechopoulos, Ioannis; Segars, William Paul; Tanaka, Rie; Vancoillie, Liesbeth

    Background

    The rapid advancement of medical technologies presents significant challenges for researchers and practitioners. While traditional clinical trials remain the gold standard, they are often limited by high costs, lengthy durations, and ethical constraints. In contrast, in-silico trials and digital twins have emerged not only as efficient and ethical alternatives but also as a complementary technology that can extend beyond classical trials to predict and design new strategies. The successful application of digital twins in industries like nuclear energy, automotive engineering, and aviation underscores their potential in human health.

    Methods

    In April 2024, Duke University hosted the first international summit on Virtual Imaging Trials in Medicine (VITM). The summit brought together over 130 experts from academia, industry, and regulatory bodies to discuss the latest developments, challenges, and future directions in this field. The event featured plenary speakers, presentations, and panel discussions, emphasizing the integration of clinical and in-silico methods to enhance medical evaluations.

    Results

    Key takeaways included the necessity of diverse and realistic digital patient representations, the integration of physics and biology in simulations, and the development of robust validation frameworks. The summit also highlighted the importance of regulatory science and the establishment of Good Simulation Practices to ensure the credibility and reliability of virtual trials.

    Conclusion

    The key discussions and insights from the VITM summit underscore the potential of in-silico trials to revolutionize medical research and patient care through personalized, efficient, and ethical evaluation methods. The collaborative efforts and recommendations from this summit aim to drive future advancements in virtual imaging trials in medicine.